Connie Celum

Summary

Publications

  1. pmc Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations
    Connie Celum
    Department of Global Health and Medicine, University of Washington, Seattle, WA 98104, USA
    J Acquir Immune Defic Syndr 63:S213-20. 2013
  2. pmc Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis
    Connie Celum
    Department of Global Health, University of Washington, Seattle, USA
    Antivir Ther 17:1483-93. 2012
  3. pmc Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence
    Connie Celum
    Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, Washington 98104, USA
    Curr Opin Infect Dis 25:51-7. 2012
  4. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
  5. pmc Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial
    Jairam R Lingappa
    Department of Global Health, Seattle, WA, USA
    Lancet 375:824-33. 2010
  6. pmc Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection
    H Nina Kim
    Department of Medicine, Schools of Medicine and Public Health, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA
    J Infect Dis 202:734-8. 2010
  7. pmc Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters
    Jairam R Lingappa
    University of Washington 325 Ninth Avenue, Box 359927 Seattle, WA 98104, USA
    AIDS Res Hum Retroviruses 29:164-71. 2013
  8. pmc Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples
    James P Hughes
    Department of Biostatistics, University of Washington, Seattle 98195 7232, USA
    J Infect Dis 205:358-65. 2012
  9. pmc Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
  10. pmc An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention
    Erin M Kahle
    Department of Epidemiology, University of Washington, Seattle, WA 98104, USA
    J Acquir Immune Defic Syndr 62:339-47. 2013

Detail Information

Publications56

  1. pmc Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations
    Connie Celum
    Department of Global Health and Medicine, University of Washington, Seattle, WA 98104, USA
    J Acquir Immune Defic Syndr 63:S213-20. 2013
    ..Three examples of combination prevention concepts are summarized for men who have sex with men in the Americas, young women in sub-Saharan Africa, and HIV serodiscordant couples...
  2. pmc Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis
    Connie Celum
    Department of Global Health, University of Washington, Seattle, USA
    Antivir Ther 17:1483-93. 2012
    ....
  3. pmc Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence
    Connie Celum
    Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, Washington 98104, USA
    Curr Opin Infect Dis 25:51-7. 2012
    ..Preexposure prophylaxis (PrEP) trials and future directions are summarized...
  4. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
    ..Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations...
  5. pmc Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial
    Jairam R Lingappa
    Department of Global Health, Seattle, WA, USA
    Lancet 375:824-33. 2010
    ..Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of acyclovir on HIV-1 progression...
  6. pmc Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection
    H Nina Kim
    Department of Medicine, Schools of Medicine and Public Health, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA
    J Infect Dis 202:734-8. 2010
    ..In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point...
  7. pmc Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters
    Jairam R Lingappa
    University of Washington 325 Ninth Avenue, Box 359927 Seattle, WA 98104, USA
    AIDS Res Hum Retroviruses 29:164-71. 2013
    ..Acyclovir use, BV among women source partners, and circumcision among male source partners may alter the set point by affecting transmitted virus inoculum in the source partners' genital compartment...
  8. pmc Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples
    James P Hughes
    Department of Biostatistics, University of Washington, Seattle 98195 7232, USA
    J Infect Dis 205:358-65. 2012
    ..Knowledge of factors that affect per-act infectivity of human immunodeficiency virus type 1 (HIV-1) is important for designing HIV-1 prevention interventions and for the mathematical modeling of the spread of HIV-1...
  9. pmc Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
    ..Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners...
  10. pmc An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention
    Erin M Kahle
    Department of Epidemiology, University of Washington, Seattle, WA 98104, USA
    J Acquir Immune Defic Syndr 62:339-47. 2013
    ..A simple risk assessment tool could be useful for identifying couples at highest risk for HIV-1 transmission...
  11. pmc Hormonal contraceptive use and risk of HIV-1 disease progression
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, Washington 98104, USA
    AIDS 27:261-7. 2013
    ..For HIV-1-infected women, hormonal contraception prevents unintended pregnancy, excess maternal morbidity, and vertical HIV-1 transmission. Hormonal contraceptives are widely used but their effects on HIV-1 disease progression are unclear...
  12. pmc Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e25828. 2011
    ..We describe the trial design and characteristics of the study cohort...
  13. pmc Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Lancet Infect Dis 12:19-26. 2012
    ..We aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners...
  14. pmc Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations
    Yanhui Lu
    Department of Pharmacology and Molecular Sciences, Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 56:2777-9. 2012
    ..59 h · μg/ml, respectively, 54% and 52% lower than values from non-Africans. Lower acyclovir concentrations may partly explain the reduced acyclovir suppression of HSV-2 genital ulcer recurrence in HPTN 039 African women participants...
  15. pmc Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men
    Ashok Cattamanchi
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Med Virol 83:1696-703. 2011
    ..In contrast, HAART was a potent inhibitor of HHV-8 replication. Studies of whether antiviral therapy in combination with ART will prevent HHV-8-associated disease appear warranted...
  16. ncbi Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: effects on HIV-1 susceptibility
    Huanliang Liu
    Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington 98195 8070, USA
    J Infect Dis 193:698-702. 2006
    ..5% in high-risk HIV-1-seronegative individuals vs. 27.6% in HIV-1-seropositive individuals; P=.0291). These findings suggest that DC-SIGNR polymorphisms may influence susceptibility to HIV-1...
  17. pmc Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study
    Jairam R Lingappa
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 4:e5272. 2009
    ..We describe the baseline characteristics of this cohort...
  18. pmc Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence
    DEBORAH J DONNELL
    Department of Global Health, University of Washington, Seattle, USA
    AIDS Behav 17:632-9. 2013
    ..e., fewer pills returned than expected) and when pill counts were missing because bottles were not returned, plasma HIV-1 RNA and GUD effects were diminished, likely indicating periods of non-adherence...
  19. pmc Quantifying ongoing HIV-1 exposure in HIV-1-serodiscordant couples to identify individuals with potential host resistance to HIV-1
    Romel D Mackelprang
    Department of Global Health, University of Washington, WA, USA
    J Infect Dis 206:1299-308. 2012
    ..We developed a novel approach for quantifying HIV-1 exposure to identify individuals remaining HIV-1 uninfected despite persistent high exposure...
  20. doi A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, WA 98104, USA
    Sex Transm Dis 37:621-8. 2010
    ..Few studies have explored contraceptive use in HIV-1 serodiscordant couples, a population at high risk for HIV-1 transmission...
  21. pmc Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters
    Mary S Campbell
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    J Infect Dis 207:1166-70. 2013
    ..Our data do not support the hypothesis that higher early viral load accounts for the rapid spread of HIV-1 subtype C in southern Africa...
  22. pmc Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    J Infect Dis 198:1804-8. 2008
    ..001]), as was cervical HIV-1 level (-0.35 log10 copies/swab, a 55% decrease [P < .001]). Suppressive HSV-2 therapy has the potential to reduce HIV-1 infectiousness and slow HIV-1 disease progression...
  23. pmc Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission
    Pamela M Murnane
    Department of Epidemiology, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 7:e51192. 2012
    ..Because the quantity of HIV-1 in plasma is the primary predictor of HIV-1 transmission, consideration of plasma viral load in ART initiation guidelines is warranted...
  24. doi Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis
    Kenneth K Mugwanya
    Department of Epidemiology, University of Washington, Seattle, WA, USA Department of Disease Control and Environmental Health, Makerere University, Kampala, Uganda
    Lancet Infect Dis 13:1021-8. 2013
    ..We studied whether the use of pre-exposure prophylaxis in HIV-uninfected men and women in HIV-serodiscordant couples was associated with increased sexual risk behaviour...
  25. pmc Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure
    Jairam R Lingappa
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e28632. 2011
    ..To minimize misclassification of HIV-1 risk, we quantified HIV-1 exposure, using data including plasma HIV-1 concentrations, gender, and condom use...
  26. pmc A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial
    Shevin T Jacob
    Department of Medicine, University of Washington, Seattle, WA, USA
    AIDS Behav 15:897-904. 2011
    ....
  27. pmc Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships
    Patrick Ndase
    Department of Global Health, University of Washington, Seattle, 98104, USA
    J Acquir Immune Defic Syndr 59:65-71. 2012
    ..As African countries scale-up couples HIV testing, little is known about sexual behaviors and HIV risk for HIV-uninfected partners in known HIV-serodiscordant relationships...
  28. pmc Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98195, USA
    Sci Transl Med 3:77ra29. 2011
    ..These data suggest that HIV-1 RNA in genital secretions could be used as a marker of HIV-1 sexual transmission risk...
  29. pmc Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk
    Jairam R Lingappa
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 5:e12598. 2010
    ....
  30. pmc Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies
    Renee Heffron
    Department of Epidemiology, University of Washington, 325 Ninth Avenue, Box 359927, Seattle, WA 98104, USA
    J Acquir Immune Defic Syndr 61:116-9. 2012
    ..Antiretroviral treatment (ART) and pre-exposure prophylaxis (PrEP) have demonstrated efficacy as new human immunodeficiency virus-1 (HIV-1) prevention approaches for HIV-1 serodiscordant couples...
  31. doi A Prospective Study of the Effect of Pregnancy on CD4 Counts and Plasma HIV-1 RNA Concentrations of Antiretroviral-Naive HIV-1-Infected Women
    Renee Heffron
    Department of Global Health, University of Washington, Seattle, WA Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya Wits Reproductive Health and HIV Institute WRHI, University of the Witwatersrand, Johannesburg, South Africa Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya Kenya Medical Research Institute, Nairobi, Kenya Department of Reproductive Health, Moi University, Eldoret, Kenya and Departments of Epidemiology and Medicine, University of Washington, Seattle, WA
    J Acquir Immune Defic Syndr 65:231-6. 2014
    ....
  32. pmc Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial
    Pamela M Murnane
    aDepartment of Epidemiology bDepartment of Global Health cDepartment of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Obstetrics and Gynaecology, University of Nairobi eDepartment of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi, Kenya fDivision of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda gDivision of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland hStatistical Center for HIV AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA iCenters for Disease Control and Prevention, Atlanta, Georgia, USA Members of the Partners PrEP Study Team listed at end of paper
    AIDS 27:2155-60. 2013
    ..One hypothesis proposed for these divergent results is that PrEP efficacy may be reduced in populations with higher HIV-1 incidence...
  33. pmc Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples
    Jared M Baeten
    University of Washington, WA, USA
    AIDS 24:737-44. 2010
    ....
  34. pmc HIV-1 prevention for HIV-1 serodiscordant couples
    Kathryn Curran
    International Clinical Research Center, Department of Global Health, University of Washington, Seattle, WA 98104, USA
    Curr HIV/AIDS Rep 9:160-70. 2012
    ....
  35. pmc Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, Washington, USA
    J Infect Dis 203:117-21. 2011
    ..No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance...
  36. pmc Daily short message service surveys to measure sexual behavior and pre-exposure prophylaxis use among Kenyan men and women
    Kathryn Curran
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    AIDS Behav 17:2977-85. 2013
    ..87). PrEP adherence was high, missed doses were correlated with sexual abstinence, and unprotected sex was not associated with decreased PrEP adherence...
  37. pmc Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial
    Connie Celum
    Department of Global Health, University of Washington, Seattle, WA, USA
    Lancet 371:2109-19. 2008
    ..We investigated whether HSV-2 suppression with aciclovir would reduce the risk of HIV-1 acquisition...
  38. pmc Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2
    C Celum
    Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA
    N Engl J Med 362:427-39. 2010
    ..Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1...
  39. pmc Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya
    Elizabeth Irungu
    Department of Epidemiology, University of Washington, Seattle, WA 98104, USA
    J Infect Dis 207:402-10. 2013
    ....
  40. pmc Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, Washington, USA
    Sex Transm Infect 87:238-41. 2011
    ..To compare the performance of the Focus HerpeSelect-2 enzyme immunoassay (EIA) with the gold standard herpes simplex virus (HSV) type 2 western blot, among HIV-1-uninfected men and women in east and southern Africa...
  41. pmc High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa
    Heidi Van Rooyen
    Human Sciences Research Council, Sweetwaters, KwaZulu Natal, South Africa
    J Acquir Immune Defic Syndr 64:e1-8. 2013
    ..For antiretroviral therapy (ART) to have a population-level HIV prevention impact, high levels of HIV testing and effective linkages to HIV care among HIV-infected persons are required...
  42. pmc Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions
    Ruanne V Barnabas
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    Curr HIV Res 10:228-37. 2012
    ..Mathematical models of HSV-2 and HIV-1 at a population level would be useful tools to estimate the potential impact and cost-effectiveness of higher dose HSV-2 suppressive therapy...
  43. pmc Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    Sex Transm Dis 39:21-4. 2012
    ..1 vs. 6.0 days) and cessation of herpes simplex virus shedding (HR = 1.88, P = 0.008; mean, 3.0 vs. 5.0 days) compared with placebo, similar to results of studies in high-income countries (ClinicalTrials.gov registration NCT00808405)...
  44. doi 'If I am given antiretrovirals I will think I am nearing the grave': Kenyan HIV serodiscordant couples' attitudes regarding early initiation of antiretroviral therapy
    Kathryn Curran
    aDepartment of Epidemiology bDepartment of Global Health cDepartment of Anthropology dDepartment of Medicine, University of Washington, Seattle, Washington, USA eJomo Kenyatta University of Agriculture and Technology fKenyatta National Hospital gKenya Medical Research Institute, Nairobi, Kenya
    AIDS 28:227-33. 2014
    ..The WHO recommends ART initiation by all HIV-infected individuals in HIV serodiscordant relationships to prevent HIV transmission, yet the acceptability of early ART among couples has not been well studied...
  45. pmc Oral antiretroviral chemoprophylaxis: current status
    Jared Baeten
    Department of Global Health, University of Washington, Seattle, Washington, USA
    Curr Opin HIV AIDS 7:514-9. 2012
    ..Preexposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use oral antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy...
  46. ncbi Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men
    H Nina Kim
    Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, 98104, USA
    J Infect Dis 194:420-7. 2006
    ..Previous studies using viral cultures rarely reported herpes simplex virus type 2 (HSV-2) isolation from the mouth. We sought to characterize oral HSV-2 shedding as detected by HSV DNA polymerase chain reaction among HSV-2-seropositive men...
  47. ncbi Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection
    Jairam R Lingappa
    Department of Medicine, University of Washington, Seattle, USA
    Drugs 67:155-74. 2007
    ..Finally, there are now also growing data describing the benefits of herpes suppression in the context of individuals co-infected with HIV/HSV-2, with additional clinical trials poised to further elucidate these issues in the near future...
  48. ncbi Management of herpes simplex virus type 2 infection in HIV type 1-infected persons
    Lara B Strick
    Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98104, USA
    Clin Infect Dis 43:347-56. 2006
    ..Studies to quantify the potential clinical and public health benefits of treating individuals who have HIV-1 and HSV-2 coinfection with anti-HSV therapy are underway...
  49. pmc Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection
    Helen Horton
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N D3 100, Seattle, WA 98109, USA
    J Virol 80:9779-88. 2006
    ....
  50. pmc Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial
    Jairam R Lingappa
    University of Washington, Department of Medicine, Seattle, Washington, USA
    PLoS ONE 3:e1411. 2008
    ..Substantial regional differences exist in HIV-1 prevalence in Africa, but regional differences in HIV-1 discordance among African couples, has not previously been reported...
  51. pmc Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis
    Jared Baeten
    Department of Global Health, University of Washington, USA
    Annu Rev Med 64:219-32. 2013
    ..Next steps in the field include rigorous evaluation of uptake and adherence to PrEP in implementation settings and research into next-generation PrEP agents with longer half-life and less user dependence...
  52. pmc Risk Factors for HSV-2 Infection among Sexual Partners of HSV-2/HIV-1 Co-Infected Persons
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, WA, USA
    BMC Res Notes 4:64. 2011
    ..abstract:..
  53. doi Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries
    Catherine Corbell
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Sex Transm Dis 37:488-93. 2010
    ..Current World Health Organization guidelines for sexually transmitted infections recommend acyclovir as first-line syndromic treatment of GUD in countries with high herpes simplex virus-2 prevalence (> or =30%)...
  54. pmc Genital herpes and human immunodeficiency virus: double trouble
    Connie Celum
    Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
    Bull World Health Organ 82:447-53. 2004
    ....
  55. ncbi Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1
    Huanliang Liu
    Department of Laboratory Medicine, University of Washington School of Medicine, 1959 N E Pacific Street, Seattle, WA 98195 8070, USA
    J Infect Dis 190:1055-8. 2004
    ..2% in ES individuals vs. 0.0% in HIV-1-seropositive individuals; P=.011)...
  56. pmc Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes
    Manish Sagar
    Division of Human Biology, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington, Seattle, USA
    J Virol 78:7279-83. 2004
    ..S. women, one U.S. man, and one Kenyan man near the time of seroconversion. These findings suggest that early HIV-1 genetic diversity is not exclusive to women from Africa or to infection with any particular HIV-1 subtype...